How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors

Barbara Cybulska, Longina Kłosiewicz−Latoszek, Peter E. Penson, Seyed Mohammad Nabavi, Carl J. Lavie, Maciej Banach

2020Progress in Cardiovascular Diseases30 citationsDOI

Topics & Concepts

MedicinePCSK9Adverse effectClinical trialSecondary preventionIntensive care medicineDiseaseLdl cholesterolCholesterolDrugEpidemiologyPharmacologyInternal medicineLDL receptorLipoproteinLipoproteins and Cardiovascular Health